Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Metastatic Liver Cancer-Pipeline Review, H1 2015

Metastatic Liver Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Metastatic Liver Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Metastatic Liver Cancer-Pipeline Review, H1 2015', provides an overview of the Metastatic Liver Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Metastatic Liver Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Metastatic Liver Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Metastatic Liver Cancer Overview 6

Therapeutics Development 7

Pipeline Products for Metastatic Liver Cancer-Overview 7

Pipeline Products for Metastatic Liver Cancer-Comparative Analysis 8

Metastatic Liver Cancer-Therapeutics under Development by Companies 9

Metastatic Liver Cancer-Therapeutics under Investigation by Universities/Institutes 10

Metastatic Liver Cancer-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Metastatic Liver Cancer-Products under Development by Companies 13

Metastatic Liver Cancer-Products under Investigation by Universities/Institutes 14

Metastatic Liver Cancer-Companies Involved in Therapeutics Development 15

AB Science 15

Arrowhead Research Corporation 16

Mirna Therapeutics, Inc. 17

Provectus Biopharmaceuticals, Inc. 18

Transgene Biotek Limited 19

Metastatic Liver Cancer-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

masitinib-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Monoclonal Antibody Conjugate to Target CEA for Metastatic Liver, Colorectal Cancer and Solid Tumor-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

MRX-34-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Oncolytic Virus for Liver Metastases and Primary Liver Tumors-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Peptide to Inhibit Hemofiltrate CC Chemokine for Metastatic Liver Cancer-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

PSL001-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

PV-10-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Stem Cell Therapy for Oncology-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

TBL-0404-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Metastatic Liver Cancer-Recent Pipeline Updates 43

Metastatic Liver Cancer-Dormant Projects 61

Metastatic Liver Cancer-Discontinued Products 62

Metastatic Liver Cancer-Product Development Milestones 63

Featured News & Press Releases 63

Mar 06, 2014: PV-10 Immune Mechanism Data to Be Presented at the American Association for Cancer Research Annual Meeting 63

Jan 14, 2014: Mirna Therapeutics Reports Expansion of Intellectual Property Estate 64

Oct 24, 2013: Provectus Awarded PV-10 Patent by U.S. Patent and Trademark Office 64

Sep 27, 2012: Provectus Pharma Expands Protocol For Phase I Liver Cancer Study 65

Appendix 66

Methodology 66

Coverage 66

Secondary Research 66

Primary Research 66

Expert Panel Validation 66

Contact Us 66

Disclaimer 67

List of Tables

Number of Products under Development for Metastatic Liver Cancer, H1 2015 7

Number of Products under Development for Metastatic Liver Cancer-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Development, H1 2015 12

Products under Development by Companies, H1 2015 13

Products under Investigation by Universities/Institutes, H1 2015 14

Metastatic Liver Cancer-Pipeline by AB Science, H1 2015 15

Metastatic Liver Cancer-Pipeline by Arrowhead Research Corporation, H1 2015 16

Metastatic Liver Cancer-Pipeline by Mirna Therapeutics, Inc., H1 2015 17

Metastatic Liver Cancer-Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 18

Metastatic Liver Cancer-Pipeline by Transgene Biotek Limited, H1 2015 19

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Stage and Target, H1 2015 22

Number of Products by Stage and Mechanism of Action, H1 2015 24

Number of Products by Stage and Route of Administration, H1 2015 26

Number of Products by Stage and Molecule Type, H1 2015 28

Metastatic Liver Cancer Therapeutics-Recent Pipeline Updates, H1 2015 43

Metastatic Liver Cancer-Dormant Projects, H1 2015 61

Metastatic Liver Cancer-Discontinued Products, H1 2015 62

List of Figures

Number of Products under Development for Metastatic Liver Cancer, H1 2015 7

Number of Products under Development for Metastatic Liver Cancer-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Products, H1 2015 12

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Top 10 Targets, H1 2015 21

Number of Products by Stage and Top 10 Targets, H1 2015 22

Number of Products by Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24

Number of Products by Top 10 Routes of Administration, H1 2015 25

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 26

Number of Products by Top 10 Molecule Types, H1 2015 27

Number of Products by Stage and Top 10 Molecule Types, H1 2015 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

Arrowhead Research Corporation

Mirna Therapeutics, Inc.

Provectus Biopharmaceuticals, Inc.

Transgene Biotek Limited

Metastatic Liver Cancer Therapeutic Products under Development, Key Players in Metastatic Liver Cancer Therapeutics, Metastatic Liver Cancer Pipeline Overview, Metastatic Liver Cancer Pipeline, Metastatic Liver Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com